Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177710 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study
A Phase 3 study of Lung Transplantation and Fungal Infections, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00177710: Completed Phase 3 study of Lung Transplantation and Fungal Infections, sponsored by University of Pittsburgh.
NCT00177710 is a Phase 3 study of Lung Transplantation and Fungal Infections that has completed, run by University of Pittsburgh. The registered enrollment target is 48 participants, below the 332-participant average among 12 other Lung Transplantation trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177710, a Phase 3 study of Lung Transplantation and Fungal Infections, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.
Conditions Studied
Interventions
- DRUG Amphotericin B
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00177710 record still lists
NCT00177710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 332-participant average among 12 other Lung Transplantation trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Lung Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Amphotericin B is the first listed.
NCT00177710 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177710 about?
NCT00177710 is a clinical study titled "Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study". The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.
What is the current status of trial NCT00177710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2006-01. Estimated completion is 2007-12.
What conditions does trial NCT00177710 study?
This clinical trial studies the following conditions: Lung Transplantation, Fungal Infections.
What interventions are being tested in trial NCT00177710?
The interventions under investigation include: Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00177710?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177710 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00177710's enrollment target sits among peer trials
48 10th of 12 higher than 3 of 12 other Lung Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
RECRUITING · Phase 2
-
Trifecta-Lung cfDNA-MMDx Study
RECRUITING
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
-
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
RECRUITING · NA
-
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia